根据名称进行药物检索

ArmonAir RespiClick 113 与 Ketoconazole (Systemic)

ArmonAir RespiClick 113 与 Ketoconazole (Systemic)互相作用以及同时服用的可能性。

检测结果:

ArmonAir RespiClick 113 <> Ketoconazole (Systemic)

现实性: 27.06.2022 评论家: 医学副博士Shkutko P.M., in

在该服务的官方手册中，已注明相关研究结果统计规定的互相作用。该互相作用或对患者健康引起不良后果，或起到良好效果。具体联合用药问题，需遵从医嘱。

用户:

药物可能会大大增加吸收的氟替卡松进入血流。你可能会更有可能经历的副作用，例如肿胀，重量增益、高血压、高血糖、肌肉软弱、抑郁症、痤疮、皮肤变薄，妊娠纹，容易瘀伤、骨密度的损失、白内障、经违规行为、过度增长的脸或身体头发和异常分配的身体的脂肪，尤其是在脸部、颈部、背部和腰部。谈谈你的医生如果你有任何疑问或关切的问题。你的医生可以规定替代品，不进行互动，或者可能需要一剂量的调整或更频繁的监测通过你的医生到安全地使用这两种药物。其他副作用可能发生的包括减少能力，对抗感染风险增加的发展中感染和反应不足的压力，如感染、外科、创伤或严重哮喘发作。儿童可能会遇到一个减少增长率由于过度影响的氟替卡松。重要的是要告诉你的医生关于所有其他药物的使用，包括维生素和草药。不停止使用任何药物，没有第一个说你的医生。

医界专家:

一般避免：共同给予有效抑制剂的CYP450 3A4可能增加系统暴露于使用氟替卡松以下鼻内管理或口服吸入。氟替卡松的经历广泛的一次通过和系统性新陈代谢通过CYP450 3A4，从而抑制同工酶可以显着提高系统的药物生物利用度。然而，在何种程度上的相互作用可能取决于路线的氟替卡松的行政和具体的制剂。在18健康者，合用氟替卡松的鼻喷雾剂(200毫克每天一次)的强有力CYP450 3A4抑制剂的利托那韦(100毫克每天两次)为7天造成大约25倍增加氟替卡松C和350倍增加在哥伦比亚团结自卫，伴随着86%下降的意思是皮质醇等离子体AUC。在另一项研究，共同给予单剂量口服吸入替卡松(1000毫克)与药物(200毫克每天一次)造成了1.9倍的增长，在血浆中的氟替卡松的曝光和45%的下降等离子皮质醇哥伦比亚联合自卫军，但是没有作用上尿排泄皮质醇。在一项研究使用鼻糠酸氟替卡松、6的20者是加服药物(200毫克每天一次7天)已经可以衡量的，但是低等级的氟替卡松糠酸相比1的20者收到安慰剂。估计有5%减少到24小时的血清皮质醇水平与药物相对于安慰剂。同样，当糠酸氟替卡松-vilanterol口吸入(200微克-25微克每天一次7天)加服用药物(400每天一次对11日)在健康科目、氟替卡松AUC增加36％，相对于合用安慰剂，增加是与一个减少27％在24小时的加权平均血清皮质醇。一项研究的17肺移植患者发现，意味着氟替卡松槽级的科目接替卡松(1毫克每日两次通过口服吸入14天)与康唑是2.5倍，观察到在科不接受伊曲康唑。临床上的、系统性的皮质激素的不利影响可能会发生关联的相互作用。肾上抑制，柯兴综合症、骨质疏松症和加重的糖尿病已报告在全世界上市后使用的口服吸入或鼻腔氟替卡松、主要是结合有利托那韦。然而，也有一些情况下报告的抑制肾上腺相关联的伴随使用吸入替卡松和唑抗真菌剂。恢复的肾上腺功能是据报在缓慢一些患者的下停止氟替卡松。调查表明，这可能是相关的极高亲油性质的氟替卡松，允许长期渗流的药物进入流通，从脂肪储存。

管理：伴随使用的大口吸入的氟替卡松的筹备工作与有效的CYP450 3A4抑制剂不是建议，除非潜在的好处大于风险的系统性的副作用。替代品的氟替卡松的，应考虑只要可能的。一个不太有效，更少的亲脂性，和/或更短的作用剂这样的作为或倍氯米松氟尼缩松可能是适当的。最低有效剂量的口服吸入皮质类固醇应当使用，并进一步调整作出必要根据的治疗反应和容忍。鼻内氟替卡松和糠酸氟替卡松-vilanterol口吸入粉可以用谨慎地结合有效的CYP450 3A4抑制剂除外，利托那韦。应监测患者的迹象和症状的hypercorticism如痤疮、皮纹、稀疏的皮肤，很容易淤伤，月球的岩相dorsocervical"水牛"驼背，双肥胖症、食欲增加，严重体重增加、水肿、高血压、多毛、多汗、近肌肉萎缩和弱点，葡萄糖的不容忍现象，恶化已存在的糖尿病、抑郁和月经失调。其他的系统性激素效果可以包括抑制肾上，免疫抑制，后被膜下白内障、青光眼、骨质流失和生长发育迟缓的儿童和青少年。以下广泛使用的一个强有力CYP450 3A4抑制剂，一种渐进的剂量减少可能需要较长的时期内，如果氟替卡松的是被撤回，从治疗，如有可能是一个重大风险的肾上抑制。迹象和症状的肾上腺功能不全，包括厌食症、低血糖、恶心、呕吐、重量损失、肌肉萎缩、疲劳、无力、头晕、姿势低血压、抑郁症和肾上腺危机表现为无力应对压力(例如疾病、感染、外科、创伤). 系统皮质激素可能是必要的，直到肾上腺功能恢复。

来源

"Product Information. Veramyst (fluticasone nasal)." GlaxoSmithKline, Research Triangle Park, NC.
"Product Information. Norvir (ritonavir)." Abbott Pharmaceutical, Abbott Park, IL.
Valin N, De Castro N, Garrait V, Bergeron A, Bouche C, Molina JM "Iatrogenic Cushing's syndrome in HIV-infected patients receiving ritonavir and inhaled fluticasone: description of 4 new cases and review of the literature." J Int Assoc Physicians AIDS Care 8 (2009): 113-21
Lonnebo A, Grahnen A, Jansson B, Brundin RM, Lingandersson A, Eckernas SA "An assessment of the systemic effects of single and repeated doses of inhaled fluticasone propionate and inhaled budesonide in healthy volunteers." Eur J Clin Pharmacol 49 (1996): 459-63
Soldatos G, Sztal-Mazer S, Woolley I, Stockigt J "Exogenous glucocorticoid excess as a result of ritonavir-fluticasone interaction." Intern Med J 35 (2005): 67-8
Nocent C, Raherison C, Dupon M, Taytard A "Unexpected effects of inhaled fluticasone in an HIV patient with asthma." J Asthma 41 (2004): 793-5
Li AM "Ritonavir and fluticasone: Beware of this potentially fatal combination." J Pediatr 148 (2006): 294-5
Woods DR, Arun CS, Corris PA, Perros P "Cushing's syndrome without excess cortisol." BMJ 332 (2006): 469-70
Jinno S, Goshima C "Progression of Kaposi sarcoma associated with iatrogenic Cushing syndrome in a person with HIV/AIDS." AIDS Read 18 (2008): 100-4
Daveluy A, Raignoux C, Miremont-Salame G, et al. "Drug interactions between inhaled corticosteroids and enzymatic inhibitors." Eur J Clin Pharmacol (2009):
Samaras K, Pett S, Gowers A, McMurchie M, Cooper DA "Iatrogenic Cushing's syndrome with osteoporosis and secondary adrenal failure in HIV-infected patients receiving inhaled corticosteroids and ritonavir-boosted protease inhibitors: six cases." J Clin Endocrinol Metab 90 (2005): 4394-8
Schmid C, Naef R, Speich R, Boehler A "Addition of inhaled fluticasone propionate to systemic immunosuppression after lung transplantation: Cushing's Syndrome in patients on itraconazole comedication." Transplantation 76 (2003): 263-4
Boorsma M, Andersson N, Larsson P, Ullman A "Assessment of the relative systemic potency of inihaled fluticasone and budesonide." Eur Respir J 9 (1996): 1427-32
Grahnen A, Eckernas SA, Brundin RM, Ling-Andersson A "An assessment of the systemic activity of single doses of inhaled fluticasone propionate in healthy volunteers." Br J Clin Pharmacol 38 (1994): 521-5
Pessanha TM, Campos JM, Barros AC, Pone MV, Garrido JR, Pone SM "Iatrogenic Cushing's syndrome in a adolescent with AIDSs on ritonavir and inhaled fluticasone. case report and literature review." AIDS 21 (2007): 529-32
Rouanet I, Peyriere H, Mauboussin JM, Vincent D "Cushing's syndrome in a patient treated by ritonavir/lopinavir and inhaled fluticasone." HIV Med 4 (2003): 149-50
Parmar JS, Howell T, Kelly J, Bilton D "Profound adrenal suppression secondary to treatment with low dose inhaled steroids and itraconazole in allergic bronchopulmonary aspergillosis in cystic fibrosis." Thorax 57 (2002): 749-50
Pearce RE, Leeder JS, Kearns GL "Biotransformation of fluticasone: in vitro characterization." Drug Metab Dispos 34 (2006): 1035-40
Brus R "Effects of high-dose inhaled corticosteroids on plasma cortisol consentrations in healthy adults." Arch Intern Med 159 (1999): 1903-8
Todd GR, Acerini CL, Ross-Russell, Zahra S, Warner JT, McCance D "Survey of adrenal crisis associated witwh inhaled corticosteroids in the United Kingdom." Arch Dis Child 87 (2002): 457-61
Arrington-Sanders R, Hutton N, Siberry GK "Ritonavir-fluticasone interaction causing Cushing syndrome in HIV-infected children and adolescents." Pediatr Infect Dis J 25 (2006): 1044-1048
Fardon TC, Lee DK, Haggart K, McFarlane LC, Lipworth BJ "Adrenal suppression with dry powder formulations of fluticasone propionate and mometasone furoate." Am J Respir Crit Care Med 170 (2004): 960-6
Lipworth BJ "Systemic adverse effects of inhaled corticosteroid therapy - A systematic review and meta-analysis." Arch Intern Med 159 (1999): 941-55
Vassiliadi D, Tsagarakis S "Unusual causes of Cushing's syndrome." Arq Bras Endocrinol Metabol 51 (2007): 1245-52
Bernecker C, West TB, Mansmann G, Scherbaum WA, Willenberg HS "Hypercortisolism caused by ritonavir associated inhibition of CYP 3A4 under inhalative glucocorticoid therapy. 2 case reports and a review of the literature." Exp Clin Endocrinol Diabetes 120 (2012): 125-7
Kedem E, Shahar E, Hassoun G, Pollack S "Iatrogenic Cushing's syndrome due to coadministration of ritonavir and inhaled budesonide in an asthmatic human immunodeficiency virus infected patient." J Asthma 47 (2010): 830-1
Hillebrand-Haverkort ME, Prummel MF, ten Veen JH "Ritonavir-induced Cushing's syndrome in a patient treated with nasal fluticasone." AIDS 13 (1999): 1803
"Product Information. Flonase (fluticasone)." Glaxo Wellcome, Research Triangle Park, NC.
"Product Information. Breo Ellipta (fluticasone-vilanterol)." GlaxoSmithKline, Research Triangle Park, NC.
Bhumbra NA, Sahloff EG, Oehrtman SJ, Horner JM "Exogenous Cushing syndrome with inhaled fluticasone in a child receiving lopinavir/ritonavir." Ann Pharmacother 41 (2007): 1306-9
Kempsford R, Norris V, Siederer S "Vilanterol trifenatate, a novel inhaled long-acting beta2 adrenoceptor agonist, is well tolerated in healthy subjects and demonstrates prolonged bronchodilation in subjects with asthma and COPD." Pulm Pharmacol Ther 26 (2013): 256-64
Molimard M, Girodet PO, Pollet C, et al. "Inhaled corticosteroids and adrenal insufficiency: prevalence and clinical presentation." Drug Saf 31 (2008): 769-74
Sastre J "Pharmacology of fluticasone propionate." J Investig Allergol Clin Immunol 7 (1997): 382-4
Gupta SK, Dube MP "Exogenous Cushing syndrome mimicking human immunodeficiency virus lipodystrophy." Clin Infect Dis 35 (2002): E69-71
Johnson SR, Marion AA, Vrchoticky T, Emmanuel PJ, Lujan-Zilbermann J "Cushing syndrome with secondary adrenal insufficiency from concomitant therapy with ritonavir and fluticasone." J Pediatr 148 (2006): 386-388
Kelly HW "Comparison of inhaled corticosteroids." Ann Pharmacother 32 (1998): 220-32
"Product Information. Flovent (fluticasone)." Glaxo Wellcome, Research Triangle Park, NC.
Naef R, Schmid C, Hofer M, Minder S, Speich R, Boehler A "Itraconazole comedication increases systemic levels of inhaled fluticasone in lung transplant recipients." Respiration 74 (2007): 418-22
Gillett MJ, Cameron PU, Nguyen HV, Hurley DM, Mallal SA "Iatrogenic Cushing's syndrome in an HIV-infected patient treated with ritonavir and inhaled fluticasone." AIDS 19 (2005): 740-1
Foisy MM, Yakiwchuk EM, Chiu I, Singh AE "Adrenal suppression and Cushing's syndrome secondary to an interaction between ritonavir and fluticasone: a review of the literature." HIV Med 9 (2008): 389-96

ArmonAir RespiClick 113

非专利名称: fluticasone

品牌: ArmonAir RespiClick 113, Arnuity Ellipta, Flovent Diskus, Flovent HFA, Flovent, Flovent Rotadisk, ArmonAir RespiClick 55, ArmonAir RespiClick 232

同义词: ArmonAir Respiclick

ArmonAir RespiClick 113是什么？